Shield Therapeutics (LON:STX) Stock Price Passes Below 50-Day Moving Average of $107.69

Share on StockTwits

Shield Therapeutics PLC (LON:STX)’s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $107.69 and traded as low as $111.00. Shield Therapeutics shares last traded at $112.00, with a volume of 6,984 shares trading hands.

Several research firms have recently weighed in on STX. FinnCap reaffirmed a “corporate” rating on shares of Shield Therapeutics in a report on Monday, June 3rd. Peel Hunt reaffirmed a “buy” rating on shares of Shield Therapeutics in a report on Thursday, May 2nd. Finally, Liberum Capital reaffirmed a “buy” rating on shares of Shield Therapeutics in a report on Wednesday, April 3rd.

The firm has a market cap of $131.14 million and a price-to-earnings ratio of -74.67.

In related news, insider James M. Karis purchased 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was bought at an average price of GBX 81 ($1.06) per share, with a total value of £3,240 ($4,233.63). Also, insider Mark Sampson purchased 22,042 shares of the business’s stock in a transaction that occurred on Thursday, April 25th. The stock was bought at an average cost of GBX 91 ($1.19) per share, with a total value of £20,058.22 ($26,209.62).

COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/4380269/shield-therapeutics-lonstx-stock-price-passes-below-50-day-moving-average-of-107-69.html.

About Shield Therapeutics (LON:STX)

Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Read More: What is the QQQ ETF?

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Elastic  Rating Lowered to Sell at Zacks Investment Research
Elastic Rating Lowered to Sell at Zacks Investment Research
Diplomat Pharmacy  Stock Rating Lowered by Zacks Investment Research
Diplomat Pharmacy Stock Rating Lowered by Zacks Investment Research
Dicerna Pharmaceuticals  Rating Lowered to Sell at Zacks Investment Research
Dicerna Pharmaceuticals Rating Lowered to Sell at Zacks Investment Research
Eastgroup Properties  Rating Lowered to Hold at Zacks Investment Research
Eastgroup Properties Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research Upgrades NOW  to “Buy”
Zacks Investment Research Upgrades NOW to “Buy”
Zacks Investment Research Downgrades Endologix  to Hold
Zacks Investment Research Downgrades Endologix to Hold


© 2006-2019 Ticker Report